DexCom (NASDAQ:DXCM) Stock Acquired Rep. Jefferson Shreve

Representative Jefferson Shreve (R-Indiana) recently bought shares of DexCom, Inc. NASDAQ: DXCM. In a filing disclosed on June 22nd, the Representative disclosed that they had bought between $15,001 and $50,000 in DexCom stock on May 8th. The trade occurred in the Representative's "CRT - STANDARD UNIT TRUST" account.

Representative Jefferson Shreve also recently made the following trade(s):

• Sold $15,001 - $50,000 in shares of Hubbell NYSE: HUBB on 5/12/2025.
• Sold $50,001 - $100,000 in shares of Trane Technologies NYSE: TT on 5/12/2025.
• Sold $15,001 - $50,000 in shares of RTX NYSE: RTX on 5/12/2025.
• Sold $50,001 - $100,000 in shares of NiSource NYSE: NI on 5/12/2025.
• Sold $50,001 - $100,000 in shares of Johnson & Johnson NYSE: JNJ on 5/12/2025.
• Sold $15,001 - $50,000 in shares of AppLovin NASDAQ: APP on 5/12/2025.
• Sold $15,001 - $50,000 in shares of Fiserv NYSE: FI on 5/12/2025.
• Sold $15,001 - $50,000 in shares of CNO Financial Group NYSE: CNO on 5/12/2025.
• Sold $50,001 - $100,000 in shares of Cboe Global Markets NASDAQ: CBOE on 5/12/2025.
• Sold $15,001 - $50,000 in shares of Lam Research NASDAQ: LRCX on 5/12/2025.

DexCom Stock Performance

NASDAQ:DXCM traded up $2.25 during mid-day trading on Friday, reaching $88.99. 3,072,147 shares of the company's stock were exchanged, compared to its average volume of 2,733,721. DexCom, Inc. has a one year low of $57.52 and a one year high of $93.25. The firm has a market capitalization of $34.89 billion, a PE ratio of 66.41, a price-to-earnings-growth ratio of 1.85 and a beta of 1.44. The business's fifty day simple moving average is $84.51 and its two-hundred day simple moving average is $80.34. The company has a debt-to-equity ratio of 0.55, a quick ratio of 1.32 and a current ratio of 1.50.

DexCom (NASDAQ:DXCM - Get Free Report) last released its quarterly earnings results on Thursday, May 1st. The medical device company reported $0.32 EPS for the quarter, missing analysts' consensus estimates of $0.33 by ($0.01). DexCom had a return on equity of 30.05% and a net margin of 12.90%. The business had revenue of $1.04 billion for the quarter, compared to the consensus estimate of $1.02 billion. During the same period in the prior year, the business posted $0.32 earnings per share. DexCom's revenue was up 12.5% compared to the same quarter last year. Analysts anticipate that DexCom, Inc. will post 2.03 earnings per share for the current fiscal year.

Analyst Ratings Changes

DXCM has been the topic of several recent analyst reports. Canaccord Genuity Group raised their target price on shares of DexCom from $103.00 to $106.00 and gave the company a "buy" rating in a report on Friday, May 2nd. Wall Street Zen raised shares of DexCom from a "hold" rating to a "buy" rating in a report on Friday, July 18th. Mizuho lifted their price target on shares of DexCom from $95.00 to $100.00 and gave the company an "outperform" rating in a report on Wednesday, July 16th. Barclays lifted their target price on shares of DexCom from $90.00 to $93.00 and gave the stock an "equal weight" rating in a research report on Monday, May 5th. Finally, Truist Financial initiated coverage on shares of DexCom in a research report on Monday, June 16th. They set a "buy" rating and a $102.00 target price on the stock. Four investment analysts have rated the stock with a hold rating, seventeen have issued a buy rating and two have given a strong buy rating to the company's stock. According to MarketBeat, DexCom has an average rating of "Moderate Buy" and an average price target of $99.60.

Institutional Trading of DexCom

A number of hedge funds and other institutional investors have recently bought and sold shares of DXCM. Nuveen LLC bought a new stake in DexCom during the 1st quarter valued at $554,893,000. Norges Bank bought a new stake in shares of DexCom in the 4th quarter worth $385,367,000. Jennison Associates LLC grew its stake in shares of DexCom by 37.7% in the 1st quarter. Jennison Associates LLC now owns 10,523,246 shares of the medical device company's stock worth $718,632,000 after acquiring an additional 2,879,489 shares in the last quarter. Massachusetts Financial Services Co. MA grew its stake in shares of DexCom by 171.0% in the 1st quarter. Massachusetts Financial Services Co. MA now owns 3,194,829 shares of the medical device company's stock worth $218,175,000 after acquiring an additional 2,015,971 shares in the last quarter. Finally, Federated Hermes Inc. grew its stake in shares of DexCom by 2,371.4% in the 1st quarter. Federated Hermes Inc. now owns 1,994,732 shares of the medical device company's stock worth $136,220,000 after acquiring an additional 1,914,019 shares in the last quarter. Institutional investors own 97.75% of the company's stock.

Insider Activity

In other news, Director Nicholas Augustinos sold 3,672 shares of the company's stock in a transaction on Monday, June 16th. The shares were sold at an average price of $82.80, for a total value of $304,041.60. Following the completion of the sale, the director owned 33,411 shares in the company, valued at $2,766,430.80. This represents a 9.90% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, EVP Sadie Stern sold 1,466 shares of the company's stock in a transaction on Thursday, June 26th. The stock was sold at an average price of $85.06, for a total transaction of $124,697.96. Following the completion of the sale, the executive vice president owned 108,155 shares of the company's stock, valued at approximately $9,199,664.30. The trade was a 1.34% decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 27,190 shares of company stock worth $2,281,732. 0.32% of the stock is owned by insiders.

About Representative Shreve

Jefferson Shreve (Republican Party) is a member of the U.S. House, representing Indiana's 6th Congressional District. He assumed office on January 3, 2025. His current term ends on January 3, 2027. Shreve (Republican Party) is running for re-election to the U.S. House to represent Indiana's 6th Congressional District. He declared candidacy for the 2026 election. Email editor@ballotpedia.org to notify us of updates to this biography. Jefferson Shreve earned a bachelor's degree from Indiana University in 1989, a graduate degree from the University of London in 1998, and a graduate degree from Purdue University in 2003. Shreve's career experience includes working as a real estate executive. Shreve was elected 7th District Vice Chairman of the Indiana Republican State Committee on January 17, 2018, and was re-elected on March 6, 2021. In 2020, he was selected as a district-level delegate to the 2020 Republican National Convention.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.